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Conclusion: Salvage I-125-BT patients can be selected based 
on their disease free survival interval after primary therapy 
and the PSA-doubling time pre-salvage, ensuring sufficient 
biochemical control of >70% until three years. 
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Purpose or Objective: To report the incidence of second 
primary cancer ( SPC) after Iodine-125 brachytherapy for 
early prostate cancer in a single institution with an intense 
urological surveillance and to compare it with the cancer 
incidence in the Australian population 
 
Material and Methods: This retrospective, single-institution 
study included 889 patients treated with Iodine-125 
brachytherapy alone. All the patients had a baseline 
cystoscopy before the implant. Data were collected on all 
subsequent SPC diagnoses. SPC incidences were retrieved for 
all type of cancers and for cancers close to the radiation 
field. Interval since the implant was evaluated for potential 
association to the treatment. Standardized incidence ratios 
(SIRs) were calculated for all cancers and for bladder cancers 
and matched with the general population. The absolute 
excess risk (AER) was expressed in relation to 10000 persons-
years in the study. Kaplan-Meier analysis was used to 
determine the actuarial second malignancy and pelvic 
malignancy rates and the death from SPC and from any cause 
 
Results: Patients were followed for a median of 4.16 (0-12) 
years with 370 (42 %) patients having 5 years or more follow 
up. 62 % patients were older than 60 years. 61 patients (6.8%) 
subsequently developed a SPC with 12 pelvic malignancies : 8 
bladder and 4 rectal cancer. The 5- and 10- year cumulative 
incidences are 6.9% (95% Confidence Interval 5.0-9.4) and 
19% (95% CI 14-26) for any second malignancy, 1.3% (95%CI 
0.6-2.7) and 3.9% (95% CI 1.9-7.8) for any pelvic malignancy 
and 1% (95% CI 0.4-24) and 3.2% (1.4-7.1) for bladder cancer, 
respectively. The SIR was significantly higher for all pelvic 
malignancies at 2.10 (95% CI 1.09-3.67) and for all bladder 
cancers at 3.33 (95% CI 1.44-6.57). In the subgroup analysis 
bladder SPC risk was higher than expected for patients under 
60 years (SIR 6.52; 95%CI 1.3-19; AER 13) and within the first 
5 years of follow up (SIR 2.9 ; 95% CI 0.97-6.95; AER 10). 
Rectal cancer SIR were not significant or close in any of the 
categories. The 5- and 10-year rates of death from SPC were 
1.9 % (95% CI 1.0-3.5) and 9.1% (95% CI 5.2-16) and from any 
cause were 3.2% (95% CI 2-5 ) and 14.4% (95% CI 9.5-21.6). On 
multivariable analysis, older age was associated with 
increased SPC risk (HR 1.05, p=0.021) , all cause mortality 
(HR 1.13, p<0.001) and mortality due to SPC (HR 1.09, 
p=0.014). Smoking status was associated with all cause 
mortality (HR 2.15, p=0.026) and with mortality from second 
malignancy (HR 2.59, p=0.045) 
 
Conclusion: There may be an increased but small risk of 
second pelvic malignancy after prostate brachytherapy. A 
tendency towards a higher risk of bladder SPC after 
brachytherapy was found in the first 5 years of follow-up , 
probably resulting from screening bias . There was no 
significant increased rate of rectal cancer in any of the 
categories. Longer follow up is needed to draw strong 
conclusions.  
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Purpose or Objective: To determine the independent effect 
of additional intraoperative adaptive C-arm cone-beam 
computed tomography (CBCT) planning versus transrectal 
ultrasound (TRUS)-guided interactive planning alone in 
primary permanent I-125 brachytherapy for prostate cancer 
on long term biochemical disease free survival (bDFS). 
 
Material and Methods: All patients with biopsy proven 
T1/T2-stage prostate cancer treated with I-125 
brachytherapy were included in this cohort. Treatments were 
performed with TRUS-guided primary brachytherapy (+/- 
neoadjuvant hormonal therapy (NHT)) in a single institution 
in the period of November 2000 to December 2014. From 
October 2006 onwards, all patients received additional 
intraoperative adaptive CBCT planning for dosimetric 
evaluation and, if indicated, subsequent remedial seed 
placement in underdosed areas (which was performed in 15% 
of all patients). These procedures lasted 1-1.5 hours and 
were performed by a team of 2 radiation oncologists and 2 
therapeutic radiographers. Pre-operative characteristics, 
follow-up PSA and mortality were prospectively registered. 
Patients were stratified into National Comprehensive Cancer 
Network (NCCN) risk groups. Kaplan-Meier analysis was used 
to estimate bDFS (primary outcome), overall survival (OS) 
and prostate cancer specific survival (PCSS) (secondary 
outcomes). Cox-proportional hazard regression was used to 
assess the independent predictive value of CBCT use on 
biochemical failure (BF) (Phoenix definition) and overall 
mortality (OM). 
 
Results: 1623 patients were included. Median follow-up was 
99 months (interquartile range (IQR) 70-115) for TRUS 
patients (n=613) and 51 months (IQR 29-70) for CBCT patients 
(n=1010). BF occurred 203 times and 206 patients died, of 
which 26 due to prostate cancer. For TRUS and CBCT 
patients, estimated 7-year bDFS was 87.2% vs. 93.5% (log 
rank: p=0.04) for low risk patients, 75.9% vs. 88.5% (p<0.001) 
for intermediate risk patients and 57.1 vs. 85.0% (p<0.001) 
for high risk patients. For TRUS and CBCT patients with low, 
intermediate and high risk disease, estimated 7-year OS was 
respectively 86.5% vs. 90.4% (p=0.11), 79.6% vs. 85.1% 
(p=0.30) and 66.4% vs. 84.2% (p=0.01). For TRUS and CBCT 
patients, 7-year PCSS was 96.0% vs. 100% (p<0.0001). After 
Cox regression, CBCT patients had lower rates of BF: HR 0.45 
(95%-CI 0.33-0.61; p<0.0001). Corrected for age, IPSA, 
Gleason grade, T-stage, NHT-status and duration of NHT use, 
year of implantation, activity of the implant and prostate 
volume, CBCT showed to be an independent predictor of BF: 
HR 0.54 (95%-CI 0.33-0.89; p=0.02). CBCT was not an 
independent predictor of OM: HR 0.66 (95%-CI 0.40-1.07; 
p=0.09). 
 
Conclusion: Additional intraoperative adaptive C-arm cone-
beam CT planning in I-125 prostate brachytherapy leads to a 
significant increase in biochemical disease free survival in all 
NCCN risk groups.  
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Purpose or Objective: In adaptive radiotherapy, deformable 
image registration (DIR) is used for contour propagation and 
dose warping. Contour evaluation is visual and qualitative 
and only accurate in high contrast regions. Dose warping 
requires fully spatial and quantitative DIR evaluation 
measures also valid in low contrast regions. While 
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quantitative measures such as the target registration error 
can be used during commissioning, such measures are not 
fully spatial and too user intensive in clinical practice. 
Therefore, we propose a fully automatic and quantitative 
approach to DIR quality assessment including multiple 
measures of numerical robustness and biological plausibility.  
 
Material and Methods: Ten head and neck cancer patients 
who received weekly repeat CT (rCT) scans were included. 
Per patient, the first rCT was deformable registered (using B-
spline DIR algorithm) to the planning CT. The ground-truth 
deformation error of this registration was derived using the 
scale invariant feature transform (SIFT), which automatically 
extracts and matches stable and prominent points between 
two images. Moreover, complementary quantitative and 
spatial measures of registration quality were calculated. 
Numerical robustness was derived from the inverse 
consistency error (ICE), transitivity error (TE), and distance 
discordance metric (DDM). For the TE calculations a third CT 
was used. The DDM was calculated using five CT sets per 
patient. Biological plausibility was based on the deformation 
vector field between the planning CT and rCT. Relative 
deformation threshold values were set based on physical 
tissue characteristics: 5% for bone and 50% for soft tissues. 
All measures were evaluated in bone and soft tissue 
structures and compared against the ground-truth 
deformation error.  
 
Results: On average, SIFT detected 133 matching points 
scattered throughout the planning CT, with a mean (max) 
registration error of 1.6 (8.3) mm. Our combined and fully 
spatial DIR evaluation approach, including the ICE, TE and 
DDM, resulted in a mean (max) error of respectively 0.6 
(2.0), 0.7 (2.7), and 0.6 (2.7) mm within the external body 
contour, averaged over all patients. The largest errors were 
detected in homogeneous regions and near air cavities. 
Furthermore, 87% of the bone and 2% of the soft tissue voxels 
were classified as unrealistic deformations. Figure 1 shows 
the planning CT, DDM, tissue deformation, and error volume 
histograms of the ICE, TE, and DDM of the body contour of 
one patient.  
 
 
Conclusion: The combination of multiple automatic DIR 
quality measures highlighted areas of concern within the 
registration. While current methods on DIR evaluation, such 
as visual inspection and target registration error are time-
consuming, local, and qualitative, this approach provided an 
automated, fully spatial and quantitative tool for clinical 
assessment of patient-specific DIR even in image regions with 
limited contrast.  
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Purpose or Objective: Various approaches have been 
proposed to select the most similar atlases to a patient for 
atlas-based auto-contouring. While it is known that increasing 
the size of an atlas database improves the results of auto-
contouring for a small number of atlases, such selection 
assumes the hypothesis that increasing the atlas pool size 
always increases the chance of finding a good match. The 
objective of this study is to test this hypothesis, and answer 
the question; “Given a large enough database of atlases, can 
single atlas-based auto-contouring ever be perfect?“. 
 
Material and Methods: 35 test cases were randomly selected 
from a dataset of 316 clinically contoured head and neck 
cases, and were auto-contoured treating each of the 
remaining cases as potential atlases to be used. Thus, results 
of contouring were available for approximately 11000 atlas-
patient pairs. Dice Similarity Coefficient (DSC), Hausdorff 
distance (HD), Average Distance (AD) and Root Mean Square 
Distance (RMSD) were computed between the auto-contours 
and the clinical contours for each structure and atlas-patient 
pair. In order to estimate achievable performance under the 
assumptions of an infinite size atlas database and “perfect” 
atlas selection, the Extreme Value Theory statistical 
technique Points over Threshold, used in other domains to 
perform tasks such as estimating the magnitude of one-in-a-
hundred-years flooding, was used to model the distribution of 
the best scores. Analysis was performed for the ten most 
commonly contoured structures within the database, with a 
minimum of 6800 atlas-patient pairs per structure being 
considered. 
 
Results: The figure shows the distribution of observed 
extreme values for the left parotid DICE scores, together with 
the model fit. 
 
For all measures and structures, the model fit indicated a 
limit on the performance in the extreme. While this is 
expected since all measures have a limit at perfection, the 
performance limit in the extreme fell short of a perfect 
result. Variation was observed between structures, with well-
defined structures performing better than more complex 
ones. This may indicate that the limit on performance 
reflects the inter-observer variation in delineation. The table 
shows the best observed score for the experiments 
performed, together with the expected achievable result 
predicted by the model assuming an atlas database of 5000 
atlases. 
